VectivBio Holding AG

VectivBio Holding AG is a clinical-stage biotechnology company, which engages in the development of treatments for severe rare conditions with significant unmet medical need. Its product pipeline include Apraglutide and CoMet. The company was founded by Luca Santarelli on May 22, 2019 and is headquartered in Basel, Switzerland.

VectivBio Holding AG is a clinical-stage biotechnology company, which engages in the discovery, development, and commercialization of treatments for severe rare conditions with significant unmet medical need. It operates through Switzerland, Canada, and the United States geographical segment. The company was founded by Luca Santarelli on May 22, 2019 and is headquartered in Basel, Switzerland.

Ironwood Pharma

BOSTON & BASEL, Switzerland--(BUSINESS WIRE)--Ironwood Pharmaceuticals, Inc. (“Ironwood”) (Nasdaq: IRWD), a GI-focused healthcare company, and VectivBio Holding AG (“VectivBio”) (Nasdaq: VECT), a global clinical-stage biopharmaceutical company pioneering novel, transformational treatments for severe rare gastrointestinal conditions, today announced the successful completion of the tender offer to purchase the outstanding ordinary shares of VectivBio (the “Shares”) for $17.00 per share in cash (.

Ironwood and VectivBio Announce the Completion of the Tender Offer for VectivBio Shares

BASEL, Switzerland, June 26, 2023 (GLOBE NEWSWIRE) -- VectivBio Holding AG (“VectivBio”) (Nasdaq: VECT), a global clinical-stage biopharmaceutical company pioneering novel, transformational treatments for severe rare gastrointestinal conditions, announced that today's extraordinary general meeting approved each of the proposals of the Board of Directors, which satisfied one of the pending conditions to consummating the tender offer by Ironwood Pharmaceuticals, Inc. (“Ironwood”) to acquire all of VectivBio's outstanding registered ordinary shares for $17.00 per share in cash (subject to deduction for any applicable withholding taxes). Consummation of the tender offer remains subject to the tender of more than 80% of the total number of VectivBio's outstanding registered ordinary shares and the other conditions described in the tender offer statement.

VectivBio Extraordinary General Meeting of Shareholders Approved All Proposals

BOSTON & BASEL, Switzerland--(BUSINESS WIRE)--Ironwood Pharmaceuticals, Inc. (“Ironwood”) (Nasdaq: IRWD), a GI-focused healthcare company, and VectivBio Holding AG (“VectivBio”) (Nasdaq: VECT), a global clinical-stage biopharmaceutical company pioneering novel, transformational treatments for severe rare gastrointestinal conditions, today announced that the waiting period under the Hart-Scott-Rodino Antitrust Improvements Act of 1976, as amended (“HSR”), in connection with Ironwood's pending ac.

Ironwood and VectivBio Announce Expiration of Hart-Scott-Rodino Waiting Period for Proposed Acquisition of VectivBio

Ironwood's drug Linzess is seeing its sales start to plateau. It could get an expanded indication for Linzess that delays a decline in revenue.

Down 7% in 2023, This Struggling Growth Stock Could Soon Make a Turnaround

NEW ORLEANS--(BUSINESS WIRE)--Former Attorney General of Louisiana Charles C. Foti, Jr., Esq. and the law firm of Kahn Swick & Foti, LLC (“KSF”) are investigating the proposed sale of VectivBio Holding AG (NasdaqGS: VECT) to Ironwood Pharmaceuticals, Inc. (NasdaqGS: IRWD). Under the terms of the proposed transaction, shareholders of VectivBio will receive $17.00 in cash for each share of VectivBio that they own. KSF is seeking to determine whether this consideration and the process that led.

VECTIVBIO INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of VectivBio Holding AG - VECT

Ironwood Pharmaceuticals' buyout deal is worth $1 billion. The attraction was VectivBio's late-stage therapy, apraglutide.

Why Shares of VectivBio Holding Are Up Today

Ironwood Pharmaceuticals said Monday it will buy VectivBio for $1 billion. The deal sent VECT stock flying, while IRWD stock skidded.

VectivBio Stock Catapults 38% After Ironwood Agrees To Buy It For $1 Billion

NEW YORK--(BUSINESS WIRE)--Halper Sadeh LLC, an investor rights law firm, is investigating whether the sale of VectivBio Holding AG (NASDAQ: VECT) to Ironwood Pharmaceuticals, Inc. for $17.00 per share is fair to VectivBio shareholders. Halper Sadeh encourages VectivBio shareholders to click here to learn more about their legal rights and options or contact Daniel Sadeh or Zachary Halper at (212) 763-0060 or sadeh@halpersadeh.com or zhalper@halpersadeh.com. The investigation concerns whether Ve.

VECT Stock Alert: Halper Sadeh LLC Is Investigating Whether the Sale of VectivBio Holding AG Is Fair to Shareholders

Ironwood Pharmaceuticals is paying $17 a share for the Swiss biotech company.

Ironwood Pharmaceuticals to Acquire VectivBio for About $1 Billion

Ironwood Pharmaceuticals Inc said on Monday it will acquire Switzerland-based drug developer VectivBio Holding AG for $1.15 billion to boost its portfolio of experimental digestive disorder drugs.

Ironwood Pharma to acquire VectivBio for $1.15 bln

Ironwood Pharmaceuticals Inc. IRWD, +2.45% said Monday it has agreed to acquire Swiss biotech VectivBio Holding AG VECT, +8.18% for $17 a share in cash, or a total of about $1 billion, net of VectivBio's cash and debt. The price is equal to a premium of about 80% over the volume-weighted average share price over the previous 90 trading days.

Ironwood Pharmaceuticals to acquire Swiss biotech VectivBio in deal valued at about $1 billion

BOSTON & BASEL, Switzerland--(BUSINESS WIRE)--Ironwood Pharmaceuticals, Inc. (“Ironwood”) (Nasdaq: IRWD), a GI-focused healthcare company, and VectivBio Holding AG (“VectivBio”) (Nasdaq: VECT), a clinical-stage biopharmaceutical company pioneering novel, transformational treatments for severe rare gastrointestinal conditions, today announced that they have entered into a definitive agreement for Ironwood to acquire VectivBio for $17.00 per share in an all-cash transaction with an estimated aggr.

Ironwood Enters into Definitive Agreement to Acquire VectivBio, a Clinical-Stage Biotech Company Pioneering Novel Treatments for Severe Rare Gastrointestinal Diseases

BASEL, Switzerland, May 10, 2023 (GLOBE NEWSWIRE) -- VectivBio Holding AG (“VectivBio”) (Nasdaq: VECT), a clinical-stage biopharmaceutical company pioneering novel transformational treatments for severe rare conditions, today published the invitation to the 2023 Annual General Meeting, which will be held on Thursday, June 1, 2023, at 3:00 p.m. CEST / 9:00 a.m. EDT at Memox (meeting room "Small Space"), Elisabethenstrasse 15, 4051 Basel, Switzerland.

VectivBio Publishes Invitation to the Annual General Meeting

VectivBio Holding AG (VECT) Q4 2022 Earnings Call Transcript

Continued Strong Progress and Momentum Across Multiple Programs with  Key Upcoming Data Milestones Beginning Q2 2023

VectivBio Reports Full Year 2022 Financial Results and Provides Business Update

VectivBio: Swiss Company With Excellent Data, Upcoming Catalysts

Management to Host Conference Call Wednesday, April 19, 2023, at 8.00 a.m. ET Management to Host Conference Call Wednesday, April 19, 2023, at 8.00 a.m. ET

VectivBio to Report Full Year 2022 Financial Results and Provide Business Update on Wednesday, April 19, 2023

Single-dose study to assess pharmacokinetics, pharmacological activity, safety and tolerability in healthy Japanese men and women Single-dose study to assess pharmacokinetics, pharmacological activity, safety and tolerability in healthy Japanese men and women

VectivBio and Asahi Kasei Pharma Announce the Start of a Phase 1 Study of Apraglutide in Japan

There could be bargains among the biotechs listed in the US. VectivBio Holding AG could be a bargain. This biotech develops a treatment that could make a valuable contribution to improving the quality of life of patients with certain bowel disorders.

VectivBio Could Appeal To A Major Pharma

-Wouter Joustra Elected to the Board of Directors -Wouter Joustra Elected to the Board of Directors

VectivBio Announces Results of Extraordinary General Meeting

BASEL, Switzerland, Nov. 16, 2022 (GLOBE NEWSWIRE) -- VectivBio Holding AG (“VectivBio”) (Nasdaq: VECT), a clinical-stage biopharmaceutical company pioneering novel transformational treatments for severe rare conditions, today published the invitation to the Extraordinary General Meeting, which will be held on Friday, December 9, 2022, at 10:00 a.m. CET / 4:00 a.m. EST at the offices of VectivBio Holding AG at Aeschenvorstadt 36, 4051 Basel, Switzerland.

VectivBio Publishes Invitation to the Extraordinary General Meeting of Shareholders

BASEL, Switzerland, Nov. 09, 2022 (GLOBE NEWSWIRE) -- VectivBio Holding AG (“VectivBio”) (Nasdaq: VECT), a clinical-stage biopharmaceutical company pioneering novel transformational treatments for severe rare conditions, today announced that Luca Santarelli, M.D., Ph.D., Founder and Chief Executive Officer of VectivBio, will be presenting at the Jefferies London Healthcare Conference on Thursday, November 17, 2022. A live webcast can be accessed through the link below.

VectivBio to Present at the 2022 Jefferies London Healthcare Conference

-Largest global Phase 3 study ever conducted in SBS-IF recruiting a total of 144 patients, stratified 50/50 for Stoma and CIC anatomical subtypes

VectivBio Announces Completion of Enrollment for Colon-In-Continuity (CIC) Cohort of STARS Pivotal Phase 3 Study Investigating Apraglutide in Short Bowel Syndrome with Intestinal Failure (SBS-IF)

BASEL, Switzerland, Oct. 18, 2022 (GLOBE NEWSWIRE) -- VectivBio Holding AG (“VectivBio”) (Nasdaq: VECT), a clinical-stage biopharmaceutical company pioneering novel transformational treatments for severe rare conditions, today announced the closing of its previously announced underwritten offering of 16,700,000 ordinary shares at an offering price of $7.50 per share. Investors who purchased shares in the offering include Cowen Healthcare Investments, Driehaus Capital Management, Eventide Asset Management, LLC, Forbion's Growth Opportunities Fund, Frazier Life Sciences, Marshall Wace, OrbiMed, Surveyor Capital (a Citadel company), TCG X, Venrock Healthcare Capital Partners and Vivo Capital, among other specialist biotech investors. Before deducting the underwriting discounts and commissions and offering expenses, VectivBio received total gross proceeds of approximately $125 million.

VectivBio Announces Closing of $125 Million Underwritten Offering of Ordinary Shares

BASEL, Switzerland, Oct. 13, 2022 (GLOBE NEWSWIRE) -- VectivBio Holding AG (“VectivBio”) (Nasdaq: VECT), a clinical-stage biopharmaceutical company pioneering novel transformational treatments for severe rare conditions, today announced the pricing of an underwritten offering of 16,700,000 ordinary shares at an offering price of $7.50 per share. Investors who have agreed to purchase shares in the offering include Cowen Healthcare Investments, Driehaus Capital Management, Eventide Asset Management, LLC, Forbion's Growth Opportunities Fund, Frazier Life Sciences, Marshall Wace, OrbiMed, Surveyor Capital (a Citadel company), TCG X, Venrock Healthcare Capital Partners and Vivo Capital, among other specialist biotech investors. Before deducting the underwriting discounts and commissions and offering expenses, VectivBio expects to receive total gross proceeds of approximately $125 million. The offering is expected to close on or about October 17, 2022, subject to satisfaction of customary closing conditions.

News for VectivBio Holding AG Stock (VECT)